Adjuvant immune checkpoint inhibitors across solid tumors: a meta-analysis of phase II-III randomized trials
Findings support the efficacy of adjuvant ICIs across multiple solid tumors, with consistent improvements in DFS/RFS and a significant pooled OS benefit, and exploratory meta-regression suggested that tumor type may contribute to between-study heterogeneity.